Nestle India responds to FSSAI notice over Lactogen Pro 1 labelling claim

Nestle India has responded to a Food Safety and Standards Authority of India (FSSAI) notice concerning the labelling of its Lactogen Pro 1 infant milk substitute. The regulator has flagged potential issues with the product's marketing claims, specifically around immunity and digestion benefits, and has also scrutinised the company's digital promotions. In response, Nestle has clarified that the product is compliant with all applicable regulations and has requested a meeting with the authorities to discuss the matter.

This development is important for investors as it highlights the strict regulatory environment for infant nutrition products in India. While the company has stated its compliance, any regulatory scrutiny can impact consumer trust and potentially lead to temporary disruptions in sales or marketing activities. The outcome of this review will be closely watched by the market to gauge the regulatory risk for the company's portfolio.

Investors should monitor the outcome of the meeting between Nestle and FSSAI. The company's ability to quickly resolve the issue and reassure consumers will be key. Additionally, keeping an eye on the broader regulatory landscape for infant formula products will provide context for the company's long-term growth prospects in this sector.